ALFA Filings
Every announcement, straight from the exchange
Every Sakar Healthcare earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements with these filters
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
Q2FY27 consolidated revenue Rs87.4 Cr (+52% YoY), EBITDA Rs24.4 Cr (28% margin), PAT Rs11.3 Cr (+149%); pitch centres on oncology integration.
Sakar Healthcare Q1 FY27 results show strong oncology pivot with 38% YoY revenue growth and 120% profit jump.
Sakar Healthcare reported strong Q1FY27 consolidated results with 38% Revenue growth and 120% PAT growth, driven by its vertically integrated oncology business and expansion into regulated markets.
Sakar Healthcare Q4 FY26 revenue grew 42% YoY to ₹71.1cr with 37% EBITDA margins. Strategy focuses on transforming into a pure-play oncology exporter via its EU GMP facility.
Sakar Healthcare Q4FY26 presentation highlights a strategic shift toward high-margin oncology, leveraging a new EU-GMP integrated API-FDF facility in Bavla to drive specialized global healthcare solutions.